MWM
CPRX

Moran Wealth Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Moran Wealth Management’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.18M Buy
168,961
+137,791
+442% +$3.28M 0.13% 218
2025
Q4 		$728K Buy
31,170
+4,998
+19% +$111K 0.02% 374
2025
Q3 		$516K Sell
26,172
-7,263
-22% -$149K 0.02% 403
2025
Q2 		$726K Buy
33,435
+2,225
+7% +$52.5K 0.02% 355
2025
Q1 		$757K Buy
31,210
+21,135
+210% +$476K 0.03% 329
2024
Q4 		$210K Buy
+10,075
New +$216K 0.01% 402

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Moran Wealth Management's CPRX Position: Q1 2026 in Review

Moran Wealth Management increased its Catalyst Pharmaceutical (CPRX) stake by 442% in Q1 2026, buying an estimated $3.28M and bringing the position to 168,961 shares worth $4.18M. The position accounts for 0.13% of the portfolio, ranked #218.

Moran Wealth Management first reported a position in CPRX in Q4 2024 and has held it in 6 quarters since. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

  • Moran Wealth Management held 168,961 shares of Catalyst Pharmaceutical worth $4.18M as of Q1 2026.
  • Moran Wealth Management bought 137,791 Catalyst Pharmaceutical shares in Q1 2026, an estimated $3.28M.
  • Catalyst Pharmaceutical made up 0.13% of Moran Wealth Management's portfolio in Q1 2026, its #218 holding.
  • Moran Wealth Management first reported a position in Catalyst Pharmaceutical in Q4 2024 and has held it in 6 quarters since.
  • 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on Moran Wealth Management's 13F filing for Q1 2026, filed 27 Apr 2026.